RADXRadiopharm Theranostics Ltdvs its industry peers
A metric-by-metric comparison of Radiopharm Theranostics Ltd against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RADX본 종목 | $3.2B#1 | — | — | 868.2x#2 | 1114.3%#1 | 20.0%#3 | -1050.6%#3 | — | — | — | -83.2%#3 | — |
| PTCHF | — | — | — | — | 475.3%#2 | 181.4%#1 | -3154.0%#6 | 12.9%#2 | — | — | — | — |
| PVCT | — | — | — | — | -45.5%#7 | 15.6%#4 | -1575.3%#4 | — | — | — | — | — |
| QNRX | $296M#2 | — | 75.3x#2 | — | — | -75.6%#7 | — | -401.8%#5 | — | — | — | — |
| QNTM | $27#4 | — | — | — | — | — | — | — | — | — | -79.0%#2 | — |
| QUCY | $61M#3 | — | 3.0x#1 | 113.8x#1 | -39.9%#6 | 24.9%#2 | -3005.0%#5 | -79.6%#4 | -203.8%#3 | — | -50.9%#1 | — |
| REGN | — | 21.5x#1 | — | — | 1.0%#3 | 2.1%#6 | 24.9%#1 | 13.4%#1 | 9.2%#1 | — | — | — |
| RFL | — | — | — | — | -4.7%#5 | 2.9%#5 | -3822.5%#7 | -44.7%#3 | -50.5%#2 | — | — | — |
| RGBP | — | — | — | — | 0.0%#4 | -90.7%#8 | -143.1%#2 | — | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-11-04.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice